Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beltavac house dust mite allergoid immunotherapy in allergic rhinitis/rhinoconjunctivitis
2018-003427-11Phase 3Active
- Sponsor
- Probelte Pharma
- Start
- Jun 2021
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of Beltavac in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC), sponsored by Probelte Pharma. Primary endpoint: Combined nasal symptom and medication score. Started Jun 2021; status: active.
02
Drugs
Beltavac
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2018-003427-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003427-11.